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A B S T R A C T
Objective: We performed a meta-analysis to evaluate the efficacy of ginseng supplementation on plasma lipid
concentration.
Methods: The search included PubMed, Scopus, ISI Web of Science, Cochrane library, and Google Scholar (up to
April 2019) to identify randomized controlled trials (RCTs) investigating the effect of ginseng supplementation
on serum lipid parameters. To estimate the overall summary effect, we used random-effects model.
Results: Twenty-seven studies comprising 35 treatment arms comprising 1245 participants fulfilled the inclusion
criteria. The meta-analysis results showed that consumption of ginseng did not significantly change the con-
centrations of total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), and high
density lipoprotein-cholesterol (HDL-C). However, subgroup analyses showed a significant lowering effect in
high dose ginseng supplementation on TC, LDL-C and TG. Also, the impact of ginseng on TC and TG was sig-
nificant in long-term interventions.
Conclusion: Further RCTs with longer supplementation durations in subjects with dyslipidemia are necessitated
for a more robust assessment of the lipid-modulating properties of this plant.
1. Introduction
Cardiovascular disease (CVD) is recognized as one of the leading
causes of early mortality, accounting for more than 30% of total death
globally.1 In recent years, CVD prevalence has markedly increased in
developing countries.2,3 Dyslipidemia is one of the most important and
modifiable CVD risk factors reported to be present in more than 90% of
patients with coronary heart disease.4,5 Dyslipidemia refers to a group
of lipid abnormalities including elevated low-density lipoprotein-cho-
lesterol (LDL-C), hypercholesterolemia, hypertriglyceridemia and low
high-density lipoprotein-cholesterol (HDL-C).6 Despite improvement in
diagnosis and treatment approaches, management of dyslipidemia re-
mains challenging. In this case, there has been growing interest in
elucidating the efficacy of other treatments with fewer side-effects;
among them, herbal medicine has received vast attention.7,8
Ginseng is an herb derived from several species of the genus Panax,
which belongs indigenously to Asia and North America, and has been
used in traditional medicine for several centuries for various diseases;
with some previous studies reporting a wide range of biological activ-
ities of ginseng, including anti-inflammatory, antioxidant, anticancer,
and anti-stress effects.9–12 Thirteen distinct species of ginseng have
been identified; the most popular and most studied species are Amer-
ican (Panax quinquefolius L) and Asian (Panax ginseng) ginseng.13 Three
types of ginseng are currently available: fresh, white and red ginseng.
White ginseng is made from peeled and dried fresh ginseng, but red
ginseng is made by steaming fresh ginseng.14,15 Red ginseng reportedly
possesses greater bioactivity than the unprocessed white ginseng
roots.16 Ginsenosides (triterpene b-glycosides) are the pharmacologi-
cally active components and are responsible for the biological functions
in ginseng. More than 150 types of ginsenosides have been identified.17
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Major ones are Rb1, Rb2, Rc, Rd, Re, Rg1, and Rf, which account for
more than 80% of the total ginsenosides in ginseng.10,18 In the gas-
trointestinal tract, these ginsenosides are changed by gut microbiota,
which improves their intestinal absorption, increases their bioactivity,
and decreases the toxicity of the metabolites.19,20
Favorable effects of ginseng on improving lipid metabolism and
blood lipids have been reported in several experimental studies.21–26
Several mechanisms have been proposed to explain the antihyperlipi-
demic effects of ginseng in humans, such as anti-inflammatory and anti-
oxidative properties, reducing hepatic cholesterol and TG levels by
activation of AMP-activated protein kinase (AMPK).23,27,28 Never-
theless, findings from human studies are inconsistent in this context.
While some studies supported the beneficial effects of ginseng supple-
mentation on blood lipid concentrations,29,30 several clinical trials have
failed to show a significant effect.17,20,31 In addition, as far as we know,
there is no comprehensive systematic review and meta-analysis, which
specifically assesses the effects of ginseng on blood lipids. Here we,
therefore, aimed to perform a systematic review and meta-analysis of
studies evaluating the effects of ginseng on lipid profile in adults.
2. Method
The current systematic review and meta-analysis was designed and
reported based on the guidelines of the preferred reporting items for
systematic reviews and meta-analyses (PRISMA).32
2.1. Search strategy
Relevant articles from the earliest available online indexing year to
April 2019 were identified through searches of the literature in PubMed
(http://www.ncbi.nlm.nih.gov/pubmed), Scopus (http://www.scopus.
com), ISI Web of Science (http://www.webofscience.com), Cochrane
library (http://www.cochranelibrary.com) and Google Scholar
(https://scholar.google.com), without language or any other restric-
tion. The following terms or keywords were used: ("Panax ginseng" OR
"ginseng" OR “Panax”) AND ("Intervention Studies" OR "intervention"
OR "controlled trial" OR "randomized" OR "randomised" OR "random"
OR "randomly" OR "placebo" OR "assignment"). Moreover, we reviewed
the reference lists from the retrieved publications and review articles to
search for additional relevant studies.
2.2. Study selection
After conducting literature search by one investigator (E.Gh), all
identified articles were exported into EndNote (version X7, for
Windows, Thomson Reuters, Philadelphia, PA, USA) to eliminate du-
plications. Then, two authors (E.Gh and A.Gh) independently reviewed
titles and abstracts of the articles to ascertain whether these studies
were eligible for our meta-analysis based on inclusion criteria. The full
text of all relevant records was then reviewed. Inclusion criteria were:
RCTs (either parallel or crossover design); (i) investigating the impact
of ginseng on plasma/serum concentrations of lipids; and (ii) with
suitable controlled design, i.e., the only difference between the control
and treatment groups was ginseng. Studies that administrated ginseng
in combination with other components and trials without sufficient
data were excluded. In the case of multiple publications from the same
trial, we selected only the most recent or informative one. Any dis-
agreements were solved through consultation with a third author (A.H).
2.3. Data extraction
The data extraction was performed by two independent authors
(E.Gh and A.Gh) and the possible discrepancies were resolved by con-
sensus. The extracted information was as follows: (i) study character-
istics (first author's last name, year of publication, location of the study,
sample size and study design); (ii) participants’ information (gender,
mean age, mean body mass index [BMI], and health status); (iii) in-
tervention details (duration of treatment and ginseng dose); and (iv)
investigated outcomes including total cholesterol (TC), triglyceride
(TG), LDL-C, and HDL-C. We contacted the corresponding authors via e-
Fig. 1. PRISMA flow diagram of study selection process.
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Table 1
Characteristics of eligible studies.
First author
(location; year)
RCT design
(blinding)
Population sex Mean
Age
(year)
Mean
BMI
(kg/m2)
Sample size
(Ginseng/Placebo)
Duration
(Weeks)
Outcomes Dose of Ginseng
(g/day)
Vaksun
(Canada; 2018)
Cross Over T2DM Both 64 27.8 24/24 8 TC, LDL-c, HDL-c 3
Beak
(Korea; 2018)
Parallel
(double)
Individuals exposed to high
stress levels
Both 40.42 22.73 32/31 6 TC,TG,LDL-c,
HDL-c
0.5
Hwang (a)
(Korea; 2018)
Parallel
(double)
Healthy(GS-3K8) Both 52 ND 14/15 12 TC, TG ND
Hwang (b)
(Korea; 2018)
Parallel
(double)
Healthy (GiNST) Both 52 ND 15/15 12 TC, TG ND
Choi
(Korea; 2017)
Parallel
(double)
Healthy Both 52.32 25.56 29/34 12 TC,TG,LDL-c,
HDL-c
1
Jong
(Korea; 2016)
Parallel
(double)
Metabolic syndrome Men 46.7 28.8 32/30 4 TC,TG, HDL-c 3
Park
(Korea; 2016)
Parallel
(double)
Healthy Both 51.15 ND 39/39 24 TC,TG,LDL-c,
HDL-c
0.75
Hong
(Korea; 2015)
Parallel
(double)
NAFLD Both 47.8 27.9 35/31 3 TC 1.35
Bang
(Korea; 2014)
Parallel
(double)
Newly Diagnosed Type 2
Diabetes Mellitus
Both 57.45 23.66 21/20 12 TC,TG,LDL-c,
HDL-c
5
Raoh
(Korea; 2014)
Parallel
(double)
T2DM Both 53.35 24.9 21/21 4 TC,TG,LDL-c,
HDL-c
2.7
Cho
(Korea; 2013)
Parallel
(double)
Overweight and obese adults Both 42.85 26.2 34/34 12 TC,TG,LDL-c,
HDL-c
6
Hassanzadeh
(Iran; 2013)
Parallel
(double)
Hyperlepidemic Both 28.45 ND 18/18 8 TC,TG,LDL-c,
HDL-c
0.5
Hosseini
(Iran; 2013)
Parallel
(double)
T2DM Both 47.05 30.25 15/15 8 TC,TG,LDL-c,
HDL-c
0.3
Kwon
(Korea; 2012)
Parallel
(double)
Obese Women 43.69 28.80 22/23 8 TC,TG, HDL-c 6
Park
(Korea; 2012)
Parallel
(double)
Metabolic syndrome Both 44.65 ND 23/25 12 TC,TG, HDL-c 4.5
Lee(a)
(Korea; 2012)
Parallel
(double)
Healthy Volunteers Men 40.30 22.6 56/57 4 TC,TG,HDL-c 0.5
Lee(b)
(Korea; 2012)
Parallel
(double)
Healthy Volunteers Men 40.30 22.6 57/57 4 TC,TG,HDL-c 1
Lee ©
(Korea; 2012)
Parallel
(double)
Healthy Volunteers Women 41.05 22.45 56/57 4 TC,TG,HDL-c 0.5
Lee (d)
(Korea; 2012)
Parallel
(double)
Healthy Volunteers Women 41.05 22.45 57/57 4 TC,TG,HDL-c 1
Kim
(Korea; 2011)
Parallel
(double)
T2DM Both 53.74 24.36 20/18 12 TC,TG,LDL-c,
HDL-c
0.78
Kim
(Korea; 2011)
Parallel
(double)
Postmenopausal Women 54.04 22.19 36/36 12 TC,TG,LDL-c,
HDL-c
3
Shin
(Korea; 2011)
Parallel
(double)
Impaired fasting glucose Both 44.4 25.15 15/15 8 TC, LDL-c, HDL-c 20
Yoon (a)
(Korea;2011)
Parallel
(double)
T2DM Both 53.75 25.8 18/18 8 TC,TG,LDL-c,
HDL-c
1.5
Yoon (b)
(Korea;2011)
Parallel
(double)
T2DM Both 53.75 24.65 18/18 8 TC,TG,LDL-c,
HDL-c
2
Yoon (c)
(Korea;2011)
Parallel
(double)
T2DM Both 52.95 25.35 18/18 8 TC,TG,LDL-c,
HDL-c
3
Reeds
(USA; 2011)
Parallel
(double)
Impaired glucous tolerance Both 46 33 5/5 4 TC,TG,LDL-c,
HDL-c
8
Rhee
(Korea; 2010)
Parallel
(double)
Hypertension Both 56.5 24.8 30/34 12 TC,TG,LDL-c,
HDL-c
3
Chung
(Korea; 2010)
Cross Over Coronary Artery Disease Both 62.4 25.5 20/20 10 TC 2.7
Ahn
(Korea; 2010)
Parallel
(double)
AMI Both 60.45 24.45 25/25 32 TC,TG,LDL-c,
HDL-c
3
Shin (a)
(Korea; 2007)
Parallel
(double)
Healthy Both 40 ND 29/29 ? TC,TG,LDL-c,
HDL-c
ND (Low dose)
Shin (b)
(Korea; 2007)
Parallel
(double)
Healthy Both 40 ND 29/29 ? TC,TG,LDL-c,
HDL-c
ND (High dose)
Andrade
(Brazile; 2007)
Parallel
(double)
Erectile dysfunction Men 53.45 ND 30/30 12 TC,LDL-c, HDL-c 1
Soo kim (a)
(Korea; 2002)
Parallel
(ND)
Healthy Women 20.57 ND 7/7 12 TC,TG,LDL-c,
HDL-c
?
Soo kim (b)
(Korea; 2002)
Parallel
(ND)
Healthy Women 21.14 ND 7/7 12 TC,TG,LDL-c,
HDL-c
?
Kim
(Korea; 2001)
Parallel
(double)
Smoker Men 23 ND 15/5 4 TC,TG,LDL-c,
HDL-c
1.8
AMI; acute myocardial infarction; T2DM, type 2 diabetes mellitus; NAFLD, nonalcoholic fatty liver disease; HC, hip circumference; ND, non-defined.
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mail in case further information was required.
2.4. Quality assessment
We assessed the methodological quality of each included trial by
using the Cochrane Collaboration’s tool, which assigns scores for fol-
lowing domains: 1) random sequence generation (selection bias); 2)
allocation concealment (selection bias); 3) blinding of participants and
personnel (performance bias); 4) blinding of outcome assessment (de-
tection bias); 5) incomplete outcome data (attrition bias); 6) selective
reporting (reporting bias); and 7) other sources of bias. According to the
recommendations of the Cochrane Handbook, a judgment of “low risk
of bias”, “high risk of bias” or “unclear risk of bias” was made in each
domain. Finally, the overall quality of individual study was considered
as good (low risk for more than 2 item), fair (low risk for 2 item), and
weak (low risk for less than 2 item).33 The quality assessment was
conducted by E.Gh and A.Gh independently and was discussed with A.H
in case of inconsistencies.
2.5. Statistical analysis
Statistical analyses were carried out using the STATA software
(version 11.0; Stata Corporation). All data were collected as means ±
standard deviation (SD) for each variable in similar unit (mg/dl) to
estimate the pooled effects. In studies in which mean change was not
directly reported in intervention and control groups, it was calculated
by the minus of the post-intervention data from the baseline value.
Also, the SD of mean change was calculated as follows: [SD= square
root [(SD pre-treatment) 2+ (SD post-treatment) 2− (2R×SD pre-
treatment× SD post-treatment)], assuming a correlation coefficient of
0.5. To make sure that our meta-analysis is not sensitive to the selected
correlation coefficient, all the analyses for each parameter was repeated
by the use of correlation coefficient of 0.2 and 0.8. When standard error
(SE) was reported in place of SD, we converted it to SD for further
analyses: SD=SE× sqrt (n); n= number of subjects. Weighted mean
differences (WMDs) and 95% confidence intervals (CIs) were calculated
for net changes by using the random-effects model which takes the
between-study heterogeneity into account. Heterogeneity among stu-
dies was assessed by the p value and I2 statistic. Substantial hetero-
geneity exists when I2 exceeds 50% or p value was less than 0.05.34 To
find the potential sources of between-study heterogeneity, we carried
out a pre-planned subgroup analysis based on gender (male, female, or
both), intervention duration (≥12 or< 12 weeks), ginseng dose
(< 1500 or ≤1500mg/day), and type of study population (healthy or
unhealthy). Heterogeneity between subgroups was evaluated using
fixed-effect model. To determine if any single clinical trial with extreme
findings had an undue influence on the overall results, sensitivity
analysis was performed. We estimated publication bias with visual in-
spection of funnel plots and Begg’s rank-correlation method. In addi-
tion, the trim-and-fill approach was performed to obtain an adjusted
effect size that takes into account publication bias. All tests were two-
tailed and p < 0.05 indicated statistical significance.
3. Result
3.1. Study selection
Our search identified 1245 articles through databases searching
(Fig. 1). After removing duplicate publications (n=210), 1035 articles
remained for screening the titles or abstracts. Of them 1001 records
were excluded due to irrelevance to the inclusion criteria and dupli-
cation. Among 34 remaining articles, 7 records were excluded due to
the following reasons: 1) without sufficient data (n= 2), 2) without a
placebo group (n=1), and 3) used mixture of ginseng with other
compounds (n=4). Finally, 27 articles,10,11,17,20,27,29–31,35–53 with 35
arms were included in the present systematic review and meta-analysis.
3.2. Study characteristics
Included studies have been published between 2001 and 2018. A
total of 1839 subjects (922 cases and 917 controls) were included in
analysis. Twenty five studies had parallel design while two studies had
Table 2
Risk of bias assessment for included randomized controlled clinical trails.
First author (publication
year)
Random sequence
generation
Allocation
concealment
Blinding of participants and
personnel
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
Vuskan (2018) L L L L L L
Beak (2018) L L L L H L
Hwang (2018) L L L L L L
Choi (2017) U L L L L L
Jung (2016) L L L U L U
Park (2016) L L L H L L
Hong (2015) L L U U U L
Bang (2014) U U L U L U
Raoh (2014) L L L L L U
Cho (2013) U U L U L U
Hassanzadeh (2013) U U L U L U
Hosseini (2013) U L L L L U
Kwon (2012) L L L L L L
Park (2012) L U L U L U
Lee (2012) L L U U L U
Kim (2011) U U L U L U
Shin (2011) U U U U L U
Yoon (2011) L L U U L L
Reeds (2011) L L L L L L
Rhee (2010) U L U U L L
Chung (2010) U U U U L L
Ahn (2010) U U H H L L
Shin (2007) U U U U U L
Andrade (2007) L U U U L L
So kim (2002) U U H U L L
Kim (2001) U U U U L U
Kim (2011) L L L U U U
L, low risk of bias; H, high risk of bias; U, unclear risk of bias.
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cross-over design.30,39 Out of 27 included studies, 22 studies performed
in South Korea,10,11,17,20,29,35–39,41–43,45–54 2 trials in Iran,27,31 1 trial in
Canada,30 1 trial in USA17 and 1 trial in Brazil.40 The intervention
period ranged between 3 and 32 weeks. Supplementation dose of gin-
seng ranged from 0.5 g to 20 g. Twenty-one of included studies were
conducted on both genders, 3 trials were conducted on men40,43,45 and
3 trials were conducted on women.29,46,47 Included studies were car-
ried-out in subjects with type 2 diabetes,20,27,30,36,44,53 impaired fasting
glucose,17,52 healthy subjects,10,38,42,46,48,51 individuals exposed to high
stress levels,11 non-alcoholic fatty liver,41 hyperlipidemic,31 post-
menopausal,29 hypertension,50 coronary artery disease,39 acut myo-
cardial infraction,35 erectile dysfunction,40 overweight and obese sub-
jects,37,47 and metabolic syndrome.43,49 Detailed characteristics of
included trial are present in Table 1.
3.3. Risk of bias assessment
Random allocation and method of random sequence generation of
participants was mentioned in 14 trials10,11,17,20,29,30,40–43,47–49,53 al-
though that was not clear in 13 trials.27,31,35–39,44–46,50–52 Fifteen trials
reported allocation concealment.10,11,15,17,20,27,30,38,41–44,47,50,53,55
Most of the included studies had low/unclear risk of bias in blinding of
participants, personnel and outcome assessors, except Park et al.,49 Ahn
et al.35 and So kim et al.46 studies. Most studies showed low/unclear
risk of bias based on incomplete outcome data and selective outcome
reporting exception Beak et al. study.11 Details of risk of bias assess-
ment are presented in Table 2.
3.4. Finding from meta-analysis
3.4.1. Effect of ginseng supplementation on TC
Among included studies, thirty-five trials reported the effect of
ginseng supplementation on TC which included a total of 1839 parti-
cipants (922 interventions, and 917 control group). Pooled effect size
showed that TC did not change following ginseng supplementation
(WMD: -2.512mg/dl, 95% CI: −9.143, 4.118; p=0.458) with sig-
nificant between study heterogeneity (I2= 91.7%, p < 0.001) (Fig. 2).
Subgroup analysis were performed based on gender (male/female/
both), dose (≤1500mg/> 1500mg), intervention duration (< 12
weeks/≥12 weeks) and study population (healthy/unhealthy).
Subgroup analysis revealed that higher doses (more than 1500mg/day
of ginseng) and longer duration (≥12 weeks) showed significant low-
ering effect of ginseng. Furthermore, ginseng supplementation showed
significant TC lowering effect in unhealthy subjects. However, there
were no significant effect for low dose supplementation, short duration
and in healthy and male subjects.
Fig. 2. Forest plot of the effect of ginseng supplementation on total cholesterol.
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3.4.2. Effect of ginseng supplementation on TG
A total of thirty studies reported triglyceride as an outcome measure
following ginseng supplementation. It covers 1594 participants (798
interventions, and 796 control group). Pooled analysis revealed no
significant effect following ginseng supplementation (WMD:
−1.022mg/dl, 95% CI: −6.513, 4.468, p= 0.715) with significant
across-study heterogeneity (I2= 80.4%, p= <0.001) (Fig. 3).
Subgroup analysis revealed significant lowering effect in high doses,
longer duration and only in healthy subjects; this effect remained non-
significant in lower doses and unhealthy subjects, as outlined in
Table 3.
3.4.3. Effect of ginseng supplementation on LDL-C
Across included datasets, twenty-four RCTs reported results for LDL-
C covering 1065 participants (535 interventions, and 530 control
group). Combined results showed no significant effect on LDL-C fol-
lowing ginseng supplementation (WMD: −3.282mg/dl, 95% CI:
−8.311, 1.747, p=0.201). However, there was significant hetero-
geneity across the included RCTs (I2= 77.4 %, p < 0.001) (Fig. 4).
Subgroup analysis showed that high doses of ginseng supple-
mentation showed significant lowering effect; effect was significant in
healthy subjects and in both duration (< 12 weeks/≥12 weeks).
3.4.4. Effect of ginseng supplementation on HDL-C
Of all 35 included trials, thirty-one studies reported the effect of
ginseng supplementation on HDL-C level which included 1673 parti-
cipants (838 interventions, and 835 control group). We found that
ginseng supplementation did not affect HDL-C significantly (WMD:
0.809mg/dl, 95% CI: −0.734, 2.352, p= 0.304) (Fig. 5). We found
significant heterogeneity across studies (I2= 80.4%, p= <0.001).
Subgroup analysis showed that HDL-cholesterol increased sig-
nificantly in low doses of ginseng supplementation and in healthy
subjects but in both duration (< 12 weeks/≥12 weeks).
3.4.5. Publication bias and Trim and Fill sensitivity analysis
Assessment of publication bias by visual inspection of funnel plot
and Begg’s test performed for possible publication bias. There was no
publication bias for LDL-C (p=0.519). However, Begg’s test showed
significant publication bias for TG (p=0.016). Funnel plots for HDL-C
and TC also showed significant publication bias among included stu-
dies. Because of significant publication bias tests, we performed the
trim and fill sensitivity analysis. The trim and fill analysis was calcu-
lated from 31 hypothesized negative unpublished studies for HDL-C.
The corrected effect size of “publication bias” unchanged; trim and fill
analysis were statistically significant as well (p < 0.001). Therefore,
results could not be changed if other new studies publish regarding
HDL-C. However, the trim and fill analysis for TG from 39 unpublished
negative studies reclined to −6.143mg/dl (95 CI%: −12.165,
−0.122), the new pooled effect size were significant (p=0.046). The
trim and fill analysis for TG also were significant (p < 0.001). The trim
Fig. 3. Forest plot of the effect ginseng supplementation on triglyceride.
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and fill sensitivity method was calculated from 51 hypothesized nega-
tive unpublished studies for TC. The corrected effect size of “publica-
tion bias” changed to −15.106mg/dl (95 % CI: −21.314, −8.899),
which was significant (p < 0.001). The sensitivity analysis was sig-
nificant (p < 0.001). It showed the significant effect of publication
bias on overall estimate of effect size.
3.4.6. Sensitivity analysis
Sensitivity analysis indicated that no study had significant impact
on the overall effect sizes of TC, LDL-C and HDL-C, However the results
of sensitivity analysis showed that removing the study by Baek et al.11
changed the overall effect of ginseng supplementation on TG level
(WMD: −3.91mg/dl, 95 CI%: −8.43, 0.615) but remained statistically
non-significant.
4. Discussion
Findings from our meta-analysis did not support the beneficial effect
of ginseng supplementation on blood TC, TG, LDL-C, and HDL-C levels.
However, in subgroup analyses, results were changed significantly
based on study population, supplement dose and duration of treatment.
To the author’s knowledge, one additional systematic review and
Table 3
Subgroup analysis to assess the effect of ginseng supplementation on lipid profile.
Subgrouped by No. of trials WMD (95% CI) P Value P for heterogeneity I2 (%) P for between subgroup heterogeneity
Total Cholesterol
Total 35 -2.512 -9.143 4.118 0.458 0.000 91.7
Gender 0.000
Male 5 1.577 -3.257 6.411 0.523 0.634 0
Female 6 −6.212 -10.480 -1.944 0.004 0.000 84.1
Both 24 −14.446 -16.604 -12.288 0.000 0.000 93.2
Dosage 0.000
≤1500mg 13 2.497 -0.490 5.485 0.101 0.148 29.5
>1500mg 16 −22.299 -24.807 -19.791 0.000 0.000 92.8
Intervention Duration (Weeks) 0.000
<12 weeks 18 1.299 -1.557 4.156 0.373 0.001 58.3
≥12 weeks 15 −20.922 -23.334 -18.510 0.000 0.000 93.7
Type of Study Population 0.000
Healthy 18 −0.411 -2.862 2.039 0.742 0.000 70.4
Unhealthy 17 −22.661 -25.278 -20.043 0.000 0.000 92.3
Low Density Lipoprotein
Total 24 -3.282 -8.311 1.747 0.201 0.000 77.4
Gender 0.000
Male 2 −16.307 -20.863 -11.751 0.000 0.010 84.8
Female 3 −18.055 -24.297 -11.814 0.000 0.410 0
Both 19 0.095 -2.718 2.908 0.947 0.001 56.6
Dosage 0.000
≤1500mg 8 3.128 -0.938 7.195 0.132 0.073 45.9
>1500mg 12 −11.091 -14.068 -8.115 0.000 0.000 74.4
Intervention Duration (Weeks) 0.036
<12 weeks 11 −5.852 -9.033 -2.671 0.000 0.000 86.1
≥12 weeks 11 −8.280 -11.703 -4.856 0.000 0.010 56.8
Type of Study Population 0.014
Healthy 11 −8.059 -10.754 -5.364 0.000 0.000 85.3
Unhealthy 13 −2.039 -6.038 1.960 0.318 0.006 56.9
High Density Lipoprotein
Total 31 0.809 -0.734 2.352 0.304 0.000 80.4
Gender 0.000
Male 5 4.860 3.602 6.117 0.000 0.000 95
Female 6 1.604 0.362 2.845 0.011 0.064 52.1
Both 20 −0.776 -1.760 0.208 0.122 0.760 0
Dosage 0.005
≤1500mg 12 2.494 1.564 3.425 0.000 0.000 88.6
>1500mg 15 0.082 -1.078 1.241 0.890 0.019 48.3
Intervention Duration (Weeks) 0.000
<12 weeks 17 1.217 0.327 2.107 0.007 0.031 42.9
≥12 weeks 12 2.620 1.553 3.688 0.000 0.000 89.7
Type of Study Population 0.001
Healthy 16 2.172 1.377 2.967 0.000 0.000 88.9
Unhealthy 15 −0.169 -1.337 0.999 0.777 0.905 0
Triglyceride
Total 30 -1.022 -6.513 4.468 0.715 0.002 48.1
Gender 0.001
Male 4 −12.311 -19.896 -4.726 0.001 0.285 20.8
Female 6 −8.789 -14.934 -2.644 0.005 0.304 17
Both 20 2.506 -2.103 7.114 0.287 0.035 39.7
Dosage 0.041
≤1500mg 11 0.520 -4.169 5.209 0.828 0.031 49.7
>1500mg 13 −6.457 -12.564 -0.351 0.038 0.109 34.2
Intervention Duration (Weeks) 0.028
<12 weeks 15 −1.857 -6.040 2.327 0.384 0.001 61.0
≥12 weeks 13 −7.596 -13.102 -2.091 0.007 0.461 0
Type of Study Population 0.507
Healthy 17 −4.694 -9.292 -0.096 0.045 0.001 60.7
Unhealthy 13 −2.445 -7.231 2.342 0.317 0.259 18.3
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meta-analysis has been done in this area, but not specifically studying
the effect of ginseng on lipid profile.56 Gui et al.56 reported an improved
lipid profile (TG, total cholesterol, and LDL-C but not HDL-C) associated
with ginseng-related therapy in patients with type-2 diabetes (T2DM)
or impaired glucose tolerance. Due to the limited number of RCTs in-
cluded (five RCTs) and therefore insufficient sample size, results of
mentioned meta-analysis must be interpreted with caution. Further-
more, study population in this study was limited only to those with
prediabetes or T2DM. Given that, RCTs included in our meta-analysis
were with different study populations, our findings seem more reliable.
Evidence from pre-clinical studies are inconsistent, however, many
support the beneficial effects of ginseng on lipid profile.22,24–26,55,57,58
Administration of ginseng saponins have been associated with lipo-
protein lipase activation in hyperlipidemic rabbits.22 Further, positive
effects of ginseng are mainly observed in vitro, or when intraperitoneal
injection is used; however, it should be considered that the lipid me-
tabolism in rats and mice is different from humans.59 Mechanistically,
ginsenosides are purportedly able to increase the accumulation of tri-
glyceride in adipose tissue as a result of its stimulating action on the
lipogenic pathway and lipoprotein lipase,55 and also promote the
synthesis of LDL-C receptors in rats.60 Therefore, the evidence from
animal studies should be verified in clinical trials.
In the present study we found no significant effect of ginseng sup-
plementation on lipid profile. The discrepancies between included
studies could be explained by several possible reasons: 1) different
sample size; 2) Intervention period: most of included studies were less
than 12 weeks, however, shorter clinical studies suggested that health
benefits of antioxidant therapy were observed after at least 12–17
months61; 3) Dose and form of ginseng used: although most of included
trials provided ginseng, the composition of the supplement were dif-
ferent, where few of included studies provided specific details regarding
the standardization of formula. Moreover, ginseng products used in
include studies varied substantially (American ginseng, Korean red
ginseng, Panax ginseng extract, fermented red ginseng, Ginsam, enzyme
treated red ginseng and protopanaxadiol-enriched ginseng extract).
Factors regarding the study design should be considered, including the
dosage and duration of intervention and participant characteristics.
Similarly, studies included were significantly different, in terms of the
dose (0.3−8 g/day) and duration of treatment (3–32 weeks). Since no
dose-escalation study has been conducted to elucidate optimal dosage,
it is unclear whether the administrated dose in the trials was adequate
to elicit a substantial, anti-hyperlipidemic effect in a clinical setting. 4)
Human body metabolism: discrepancy between pre-clinical data and
our results may be explained by limited systemic bioavailability of
ginseng metabolites after oral administration, which can limit their
efficacy in humans.17 In addition, ginsenosides are transformed sub-
stantially by intestinal flora after oral ingestion.39 Thus, the composi-
tion and distribution of gut microbiota are likely influential, and, in-
deed, warrant further investigation.
The most bioactive compounds in ginseng are ginseng-specific sa-
ponins or ginsenosides, which are comprised of a steroid skeleton and
sugar molecules. The type, number and position of the sugars determine
their structure and function. Different ages and species of ginseng, as
well as, various processing or extraction methods and part of the plant
(root, leaf or berry), lead to variability in ginsenoside composition of a
product and finally the antihyperlipidemic efficacy of that product.53,62
Fig. 4. Forest plot of the effect of ginseng supplementation on LDL- cholesterol.
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In this case, protopanaxodial-to-protopanaxotrial ratio (PPD:PPT) has
been proposed to be influential.63 The discrepancy between the findings
from studies investigating the antihyperlipidemic properties of ginseng
on humans could be attributed partly to these differences.
In the present study, we observed significant evidence of between
study heterogeneity in most cases. Subgroup analysis revealed that
supplement dosage, duration of intervention and health status of par-
ticipants significantly affect the impact of ginseng on blood lipids. The
lowering effect of ginseng supplementation on TC, LDL-C and TG was
significant with higher doses (≥1500mg/day) of treatment. Based on
the overall findings of a meta-analysis on 26 statin trials, that every
38.7mg/dl of reduction in serum LDL-C, induced a 22% decrease in
major vascular events,64 the abovementioned reduction in serum LDL-C
level, would be of a great benefit, regarding clinical outcomes. Fur-
thermore, a 23.16mg/dl difference in TC level, has been reported to
cause a 27% relative difference in coronary risk.65 Additionally, the
impact of ginseng on TC and TG was significant in studies with longer
duration of intervention (≥12 weeks). In this case, we found a
-7.59mg/dl reduction in serum TG concentrations, in long-term trials.
Based on epidemiological evidence, increased TG or triglyceride-rich
lipoproteins can be considered as an additional cause of cardiovascular
disease and all-cause mortality.66
Several mechanisms have been proposed to explain the beneficial
effects of ginseng on blood lipids, including anti-inflammatory and anti-
oxidative properties of ginseng, regulating lipoprotein metabolism
through alteration of PPARγ expression and reducing hepatic choles-
terol and TG levels by activation of AMP-activated protein kinase
(AMPK) and inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A
reductase (HMGCR) expression.23,27,28 The lack of any significant effect
in some studies has been attributed to short duration of treatment or
lower dosage of ginseng.20,27,31,50 Interestingly, HDL-C has reportedly
been increased in studies using low doses of ginseng, however, we could
not delineate any reason for this finding, and represents an area of
interest for future research.
The present meta-analysis has several limitations which should be
considered when interpreting the results. First, studies included were
highly varied in terms of type and dosage of ginseng products used,
which might lead to different results, whilst the lack of standardization
of ginseng formulas presents issues. Second, follow-up duration and
sample sizes were not sufficient in several included trials. Third, most
studies did not adjust their results for confounding variables; there are
several parameters which must be considered in this context, including
diet,67–69 weight70 and exercise.71 Finally, significant heterogeneity
was observed for all blood lipids, which was not explained by subgroup
analyses completely. This meta-analysis also has several strengths. First,
we conducted a comprehensive search to find all relevant published
articles. In addition, all studies included were RCTs, which provide the
most reliable, causal results, in comparison with observational studies.
Fig. 5. Forest plot of the effect of ginseng supplementation on HDL- cholesterol.
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5. Conclusion
In conclusion, the results from present systematic review and meta-
analysis did not support the beneficial effects of ginseng supplementa-
tion on blood lipids, including TC, TG, LDL-C, and HDL-C. However,
subgroup analyses showed a significant lowering effect in high dose
ginseng supplementation on TC, LDL-C and TG. Also, the impact of
ginseng on TC and TG is significant in long-term interventions. Finally,
well-designed, longer duration clinical trials with standardized for-
mulas are needed to elucidate the effectiveness of ginseng more con-
clusively.
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